Free tool
FAERS Monitor: Estradiol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020538 or its brand name (Estradiol, Estradiol). Reports on generic versions are filed under their own applications.
Reports
49,280
Serious
23,503
48% of reports
Hospitalization
7,485
Death reported
922
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,108
- headache3,056
- nausea3,025
- fatigue3,017
- off label use2,458
- pain2,204
- diarrhoea2,023
- dizziness1,839
- product adhesion issue1,766
- arthralgia1,724
- breast cancer female1,724
- rash1,640
- pruritus1,634
- dyspnoea1,593
- hot flush1,454
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 543 |
| 2005 | 601 |
| 2006 | 444 |
| 2007 | 1,502 |
| 2008 | 496 |
| 2009 | 683 |
| 2010 | 1,067 |
| 2011 | 964 |
| 2012 | 1,282 |
| 2013 | 941 |
| 2014 | 1,165 |
| 2015 | 2,069 |
| 2016 | 2,638 |
| 2017 | 2,338 |
| 2018 | 2,607 |
| 2019 | 3,001 |
| 2020 | 3,034 |
| 2021 | 2,870 |
| 2022 | 3,164 |
| 2023 | 3,628 |
| 2024 | 3,783 |
| 2025 | 5,357 |
| 2026 | 5,102 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,879 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,724 | 29.4 | 28.0 | 44,237 |
| product adhesion issueSignal | 1,766 | 22.1 | 21.1 | 33,923 |
| hot flushSignal | 1,454 | 8.4 | 8.0 | 9,288 |
| headacheSignal | 3,056 | 2.1 | 2.0 | 1,770 |
| pruritus | 1,634 | 1.8 | 1.7 | 609 |
| arthralgia | 1,724 | 1.8 | 1.7 | 589 |
| fatigue | 3,017 | 1.7 | 1.6 | 811 |
| nausea | 3,025 | 1.6 | 1.6 | 769 |
| rash | 1,640 | 1.6 | 1.5 | 383 |
| dizziness | 1,839 | 1.6 | 1.5 | 394 |
| pain | 2,204 | 1.5 | 1.5 | 419 |
| diarrhoea | 2,023 | 1.3 | 1.3 | 178 |
| drug ineffective | 4,108 | 1.3 | 1.3 | 360 |
| dyspnoea | 1,593 | 1.2 | 1.1 | 55 |
| off label use | 2,458 | 1.2 | 1.2 | 84 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.